Medical device mergers and acquisitions continued at a steady pace throughout the first half of 2026. The year started off with two large deals: Boston Scientific announced plans to buy Penumbra for $14.5 billion and Abbott closed its $21 billion purchase of cancer test firm Exact Sciences.
In April and May, companies announced several smaller acquisitions. Some highlights include Stryker’s buy of Amplitude Vascular Systems for up to $835 million, bringing the company a treatment for peripheral arterial disease, and Roche’s planned purchase of digital pathology firm PathAI for up to $1.05 billion.
Several medtech firms have also announced major divestitures in the past year. BD sold its biosciences and diagnostics businesses to Waters and Medtronic completed its spinoff of diabetes tech business MiniMed. Johnson & Johnson has also shared plans to divest its orthopedics segment.
Here are the top M&A deals so far this year:
